Agreement - October 16, 2014
Xbrane in Indian agreement
Xbrane Bioscience has signed an agreement with an Indian company in helping them to develop a bacterial system for protein production. Under the agreement, Xbrane will develop a system for the manufacturing of a biosimilar protein pharmaceutical. In an interview with Kemivärlden Biotech Xbrane Biosciences’ CEO Siavash Bashiri says that they cannot reveal which pharmaceutical […]
Agreement - October 13, 2014
Enzymatica expands in Denmark
Enzymatica has signed agreements with the pharmacy chain Pharma+ and the wellness chain Matas in Denmark to sell ColdZyme. From November this year, ColdZyme will be available on the Danish market, and thus in all of Scandinavia. “According to plan, we are expanding to our neighboring countries using our own sales organization, building a platform of […]
Agreement - October 9, 2014
Dilafor signs agreement with Opocrin
Swedish Dilafor AB and Italian Opocrin S.p.A. have entered into a commercial supply and partnership agreement. In the agreement, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for Dilafor’s candidate drug tafoxiparin for the European, US, CIS and Japanese markets. Opocrin will also supply manufacturing services during […]
Agreement - September 17, 2014
AstraZeneca and Eli Lilly enter agreement
The two companies have announced an alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer’s disease. The aim is to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer’s disease. Lilly will lead clinical development, working with researchers from AstraZeneca’s Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible […]
Agreement - September 16, 2014
BioLamina enters agreement with Corning
Corning Incorporated has entered into an agreement with BioLamina to manufacture and package the Recombinant Laminin-521 (rLaminin-521) pluripotent stem-cell and neural stem-cell growth matrix. “As cell-culture and cell-therapy technologies progress, it is increasingly important to offer today’s researchers more powerful and reliable culture systems,” said Kristian Tryggvason, Ph.D., CEO, BioLamina. “Through this agreement with Corning, […]
Agreement - September 9, 2014
NeuroVive signs major agreement
The Swedish mitochondrial medicine company has signed an exclusive agreement worth USD 150 million with OnCore BioPharma. The agreement regards outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection. NeuroVive states that deal can give the company in total USD150 million in conditional milestone payments plus royalties on future drug sales. “After extensive discussions with a […]
